QIBA PET Amyloid Biomarker Committee (BC)
11 November 2016 at 9:00 AM CT (GMT-6)
Call Summary

In attendance:

<table>
<thead>
<tr>
<th>Satoshi Minoshima, MD, PhD  (Co-Chair)</th>
<th>Dawn Matthews, MS</th>
<th>RSNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Perlman, MD  (Co-Chair)</td>
<td>Annette Schmid, PhD</td>
<td>Joe Koudelik</td>
</tr>
<tr>
<td>Edward Jackson, PhD</td>
<td>Na Sun, PhD</td>
<td>Susan Weinmann</td>
</tr>
<tr>
<td>Adriaan Lammertsma, PhD</td>
<td>Jean-Luc Vanderheyden, PhD</td>
<td></td>
</tr>
</tbody>
</table>

Moderator: Dr. Perlman

Previous Call Summary: The Oct 14th call summary was approved as written

QIBA Kiosk Poster Design and Content Discussed:
- Poster has been designed and submitted to RSNA for printing
- Design focus for 2017 will be more images/less text
- Committee members encouraged to volunteer for the Meet-the-Expert (MTE) poster sessions via the Google sign-up sheet {Please select appropriate BC tab at the bottom of the form.}
- Focus of MTE sessions is to promote awareness of the BC and overall QIBA activities regarding amyloid Profile status, groundwork projects, and possible expansion to imaging tau pathology and or PET-MR Profile activities

Reminders for RSNA 2016 Annual Meeting:
- The QIBA Working Meeting will be held on Wednesday, November 30th from 2:30 – 5 pm (6 pm optional)
- NM CC leaders are working on a strategy for this group discussion
- QIBA breakout sessions for nuclear medicine will be held in one room as a convenience for members on multiple BCs
- BCs may split into groups depending on attendance
- Please RSVP for the QIBA Working Meeting via Google Form so leaders can plan Breakout Session Content

Profile: Status Update:
- Dr. Perlman encouraged committee members to review the entire Profile and provide feedback; a section-by-section review by content experts would also provide valuable feedback
- Ms. Matthews commended the efforts, multiple perspectives and technical consideration of all content submitters, but cautioned that end-users may misinterpret the claim language
- The Profile’s change metric is based on conformance to technical requirements to reduce variability affecting measurements; biology doesn’t allow for such repeatability
- To be of use to Pharma, the Profile must align both accurate technical and biological change measurements
- Ms. Matthews offered to draft text addressing the lack of context regarding biological change metrics
- Dr. Subramaniam will be asked to provide literature citations regarding time-of-flight and point-spread-function
- Dr. Perlman created a spreadsheet of open issues that will be circulated for feedback along with the Profile
- An at-a-glance graphic was suggested to help users better assess motion and reference regions
- Subject weight and height issues/details to be removed from the normative text
- DRO series being created by Dr. Kinahan (Rnd-6 project) to address workstation conformance testing specifics; this will not delay release of the Public Comment version, but will be indicated as Open Item
- Appendix B needs to be written. This will draw from Dr. Subramaniam’s meta-analysis work and references
• Appendix E (reference section) needs to be tidied-up; a champion is needed to review and clean; this is not expected to delay release to Public Comment
• Drs. Perlman and Obuchowski to follow up offline regarding last few statistical issues

Profile: Next Steps and Milestones:
• Goal to finish internal BC review in two weeks (soon after RSNA 2016) and release for Public Comment in January 2017
• Dr. Vanderheyden offered assistance with reaching out to assorted Pharma contacts
  o Drs. Perlman and Vanderheyden to follow up offline regarding old vs. new Pharma contacts
• Staff to post clean Profile on the Wiki
• Staff to circulate clean and marked-up Profile (and issues spreadsheet) to BC for review/feedback